Pizotifen

Pizotifen
Clinical data
Trade names	Sandomigran
AHFS/Drugs.com	International Drug Names
Pregnancy; category	AU: B1; ;
Routes of; administration	Oral
ATC code	N02CX01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only);
Pharmacokinetic data
Bioavailability	78%
Protein binding	91%
Metabolism	Glucuronidation (main route). N-glucuronide accounts for >50% of plasma and 60–70% of urinary excreted drug
Elimination half-life	23 hours
Excretion	18% feces, 55% urine (both as metabolites)
Identifiers
	IUPAC name 4-(1-methyl-4-piperidylidine)-9,10-dihydro -4H-benzo-[4,5]cyclohepta[1,2]-thiophene;
CAS Number	15574-96-6 ;
PubChem CID	27400;
IUPHAR/BPS	93;
DrugBank	DB06153 ;
ChemSpider	25497 ;
UNII	0BY8440V3N;
KEGG	D05523 ;
ChEMBL	ChEMBL294951 ;
CompTox Dashboard (EPA)	DTXSID6023490 ;
ECHA InfoCard	100.036.014
Chemical and physical data
Formula	C19H21NS
Molar mass	295.44 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES s1c3c(cc1)C(\c2c(cccc2)CC3)=C4/CCN(C)CC4;
	InChI InChI=1S/C19H21NS/c1-20-11-8-15(9-12-20)19-16-5-3-2-4-14(16)6-7-18-17(19)10-13-21-18/h2-5,10,13H,6-9,11-12H2,1H3 ; Key:FIADGNVRKBPQEU-UHFFFAOYSA-N ;
	(what is this?) (verify)

Pizotifen (INN) or pizotyline (USAN), trade name Sandomigran, is a benzocycloheptene-based drug used as a medicine, primarily as a preventive to reduce the frequency of recurrent migraine headaches.^[1]

^ Stark RJ, Valenti L, Miller GC (August 2007). "Management of migraine in Australian general practice". The Medical Journal of Australia. 187 (3): 142–146. doi:10.5694/j.1326-5377.2007.tb01170.x. PMID 17680738. S2CID 10357983.

[pmid17680738-1] Stark RJ, Valenti L, Miller GC (August 2007). "Management of migraine in Australian general practice". The Medical Journal of Australia. 187 (3): 142–146. doi:10.5694/j.1326-5377.2007.tb01170.x. PMID 17680738. S2CID 10357983.

[1]